Genetics and Genomics Grand Rounds: ‘Huntington’s Disease’

Wednesday, October 16, 2019 - 4:00pm to 5:00pm
Event Location: 

University of Arizona College of Pharmacy
Drachman Hall, Room B111

1295 N. Martin Ave.
Tucson, AZ 85719
(Map of Drachman Hall)
 

Share: 

The Genetics and Genomics Grand Rounds are presented by the University of Arizona Health Sciences Center for Applied Genetics and Genomic Medicine:

SPEAKER: Ignacio Munoz-Sanjuan, PhD | Vice President, Translational Biology, CDHI Foundation, Los Angeles

“Update on Huntington's Disease: Insights and Therapeutic Strategies”

Wednesday, Oct. 16, 2019 | 4 - 5 p.m. | MRB Room 102
- Refreshments Available after 3:45 p.m. -
CME CREDIT AVAILABLE

For more information, please visit: https://precisionhealth.uahs.arizona.edu/genetics-genomics-grand-rounds

Livestream available at: https://bit.ly/2jXind3

Speaker Host: Dr. Linda Restifo | LLR@email.arizona.edu

Event flyer (please view, post and share with colleagues) gggr_i.munoz-sanjuan_flyer_10-16-19.pdf 

About the Presenter:
Dr. Ignacio Muñoz-Sanjuan is an expert in neurodevelopment, neural physiology and stem cells, concentrating on the identification and pharmacological modulation of novel pathways for the treatment of neurodegenerative disorders. He completed his doctorate in molecular biology and genetics at Johns Hopkins University School of Medicine and received a Helen Hay Whitney Foundation Fellowship to investigate the molecular basis of early neural development at Rockefeller University. After this postdoctoral fellowship, he joined Merck Sharp & Dohme in the United Kingdom as a research fellow. There, he led a program on the pharmacological modulation of targets critical for adult neural stem cell proliferation and synaptic plasticity that focused on finding new treatments for psychiatric conditions. He then joined Amgen Inc. as a senior scientist, where he led several projects in the area of neurodegeneration, with an emphasis on non-amyloid strategies for Alzheimer's disease. He joined CHDI, a U.S.-based non-profit biomedical foundation that aims to “discover and develop drugs that delay or slow the progression of Huntington's disease,” in 2007. CHDI funds dozens of academic research labs, collaborates with many industry and other partners worldwide, and coordinates with NIH. As vice president of Translational Biology, Dr. Muñoz-Sanjuán oversees a large portfolio focused on two major goals. The first is based on molecular strategies to lower levels of the toxic form of HTT which causes HD-type neurodegeneration. The second is based on neurophysiological methods to normalize brain circuitry for symptomatic relief. Dr. Muñoz-Sanjuán also founded Factor-H, a non-profit NGO that supports families in Latin America impacted by Huntington’s disease.

Questions? Email Kathy Ben: kben@email.arizona.edu

Event Coordinator: 
Kathy Ben | Program Coordinator, Molecular Medicine Graduate Program
(520) 626-2713
Event Contact Department: 
University of Arizona Health Sciences Center for Applied Genetics and Genomic Medicine